Dr. Herbst on a Smoking Cessation Trial for Lung Cancer

Roy S. Herbst, MD, PhD
Published: Tuesday, May 30, 2017



Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Smoking is the cause of lung cancer in over 80% of patients, explains Herbst. When people come in to be screened it is an important time to discusses the importance of smoking cessation.

It is being investigated if positive reinforcement has more of an impact on a patient looking to quit smoking, states Herbst.
 


Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Smoking is the cause of lung cancer in over 80% of patients, explains Herbst. When people come in to be screened it is an important time to discusses the importance of smoking cessation.

It is being investigated if positive reinforcement has more of an impact on a patient looking to quit smoking, states Herbst.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x